Cannabis marketing and the foggy regulatory landscape
It’s my belief that the FDA will turn a blind eye to CBD-based products, especially at the national retailers as long as the manufacturers do not make unsubstantiated therapeutic claims.
It’s my belief that the FDA will turn a blind eye to CBD-based products, especially at the national retailers as long as the manufacturers do not make unsubstantiated therapeutic claims.
Is it a product or a distinctive lifestyle? I dive into how cannabis companies today need to be extra creative when it comes to marketing their brand and messaging, ultimately changing the perception of the stigmatized industry.